Appendix 5
Clinical Protocol 931-1309

"Determination of Comparative Antiplaque/Antigingivitis Efficacy of Essential Oil-Containing Mouthrinses Using an Experimental Gingivitis Model"
Consumer Healthcare Research and Development

CLINICAL PROTOCOL

PROTOCOL #931-1309

TITLE: DETERMINATION OF COMPARATIVE ANTIPLAQUE/ANTIGINGIVITIS EFFICACY OF ESSENTIAL OIL-CONTAINING MOUTH RINSES USING AN EXPERIMENTAL GINGIVITIS MODEL

Investigator Name: TBD

MAY 9, 2000

CONFIDENTIAL
TITLE: DETERMINATION OF COMPARATIVE ANTIPLAQUE/ANTIGINGIVITIS EFFICACY OF ESSENTIAL OIL-CONTAINING MOUTHRINSES USING AN EXPERIMENTAL GINGIVITIS MODEL

Consumer Healthcare Research and Development Colleagues:

Christine H. Charles, R.D.H.  
Senior Manager Clinical Research  
Dental Affairs

Signature _______________ Date _______________

Scott Harper, Ph.D.  
Section Director  
Oral Care Technology Development

Signature _______________ Date _______________

Kon K. Fung, Ph.D.  
Senior Director  
Statistics and Data Management

Signature _______________ Date _______________

Judith M. Sills, Pharm.D.  
Senior Director  
U.S. Regulatory Affairs and Global Safety

Signature _______________ Date _______________

Michael L. Barnett, D.D.S  
Senior Director  
Dental Affairs/Technology Development

Signature _______________ Date _______________

CONSUMER HEALTHCARE RESEARCH AND DEVELOPMENT  
DIVISION OF WARNER-LAMBERT COMPANY

Dental Affairs Department  
170 Tabor Road  
Morris Plains, NJ 07950

Phone: (973-385-3066)  
Fax: (973-385-4400)

The above signed confirms herewith to have read and understood this trial protocol and attached appendices, furthermore, to accomplish this study according to the protocol and the Good Clinical Practice guidelines, as well as local regulations, and to accept respective revisions conducted by authorized personnel of Consumer Healthcare Research and Development and by competent authorities.
PROTOCOL FOR CONSUMER HEALTHCARE RESEARCH AND DEVELOPMENT
CLINICAL TRIAL

TITLE: DETERMINATION OF COMPARATIVE
ANTIPLAQUE/ANTIGINGIVITIS EFFICACY OF ESSENTIAL OIL-CONTAINING
MOUTHRINSES USING AN EXPERIMENTAL GINGIVITIS MODEL

TIME PERIOD AND NUMBER OF SUBJECTS

A. Anticipated Starting Date of Study: 
   Anticipated Starting Date for Site: 

B. Anticipated Completion Date

C. Anticipated Number of Subjects for Site:

D. Anticipated Number of Sites:

E. Anticipated Number of Subjects for Study:

Principal Investigator(s):
, D.D.S. 

Signature Date

Subinvestigator(s):

Institutional Review Board/Ethics Committee:
Name:
Address

Laboratory(ies):
Name: NA
Address:

The above signed confirms herewith to have read and understood this trial protocol and
attached appendices, furthermore, to accomplish this study according to the protocol
and the Good Clinical Practice guidelines, as well as local regulations, and to accept
respective revisions conducted by authorized personnel of Consumer Healthcare
Research and Development and by competent authorities.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td>2. STUDY OBJECTIVES</td>
<td>1</td>
</tr>
<tr>
<td>3. ETHICAL AND LEGAL CONSIDERATIONS</td>
<td>1</td>
</tr>
<tr>
<td>4. STUDY DESIGN</td>
<td>2</td>
</tr>
<tr>
<td>4.1 Target Population</td>
<td>2</td>
</tr>
<tr>
<td>4.2 Screening Visit</td>
<td>2</td>
</tr>
<tr>
<td>4.3 Admission</td>
<td>2</td>
</tr>
<tr>
<td>5. STUDY POPULATION</td>
<td>2</td>
</tr>
<tr>
<td>5.1 Source and Number of Subjects</td>
<td>2</td>
</tr>
<tr>
<td>5.2 Subject-Selection Criteria</td>
<td>3</td>
</tr>
<tr>
<td>5.2.1 Inclusion Criteria</td>
<td>3</td>
</tr>
<tr>
<td>5.2.2 Exclusion Criteria</td>
<td>3</td>
</tr>
<tr>
<td>5.3 Prohibited/Allowable Medications or Precautions</td>
<td>4</td>
</tr>
<tr>
<td>6. STUDY METHODOLOGY</td>
<td>4</td>
</tr>
<tr>
<td>6.1 Efficacy Assessments</td>
<td>4</td>
</tr>
<tr>
<td>6.1.1 Primary Efficacy Parameter(s)</td>
<td>4</td>
</tr>
<tr>
<td>6.1.2 Secondary Efficacy Parameter(s)</td>
<td>4</td>
</tr>
<tr>
<td>6.2 Oral Tissue Assessments</td>
<td>4</td>
</tr>
<tr>
<td>6.2.1 Adverse Event Reporting</td>
<td>4</td>
</tr>
<tr>
<td>6.2.1.1 Serious Adverse Events</td>
<td>5</td>
</tr>
<tr>
<td>6.2.1.2 Adverse Event Follow-up</td>
<td>5</td>
</tr>
<tr>
<td>6.2.1.3 Other Safety Monitoring</td>
<td>6</td>
</tr>
<tr>
<td>6.3 Removal of Subjects From the Study</td>
<td>6</td>
</tr>
<tr>
<td>6.4 Study Completion</td>
<td>6</td>
</tr>
<tr>
<td>7. STUDY TREATMENT</td>
<td>6</td>
</tr>
<tr>
<td>7.1 Description of Products</td>
<td>6</td>
</tr>
<tr>
<td>7.2 Blinding</td>
<td>6</td>
</tr>
<tr>
<td>7.3 Regimen</td>
<td>7</td>
</tr>
<tr>
<td>7.4 Compliance and Return of Unused Supplies</td>
<td>7</td>
</tr>
<tr>
<td>8. DATA COLLECTION</td>
<td>7</td>
</tr>
<tr>
<td>9. DATA ANALYSIS AND STATISTICAL CONSIDERATIONS</td>
<td>8</td>
</tr>
<tr>
<td>9.1 Data Analysis</td>
<td>8</td>
</tr>
<tr>
<td>9.2 Statistical Power and Sample Size Considerations</td>
<td>9</td>
</tr>
<tr>
<td>9.3 Oral Tissue Parameters</td>
<td>9</td>
</tr>
<tr>
<td>10. REFERENCES</td>
<td>9</td>
</tr>
<tr>
<td>11. LIST OF APPENDICES</td>
<td>10</td>
</tr>
<tr>
<td>A  Timetable and Visits and Procedures</td>
<td>A-1</td>
</tr>
<tr>
<td>B  Study Efficacy Procedures and Study Parameters Definitions</td>
<td>B-1</td>
</tr>
<tr>
<td>C  Detailed Oral Tissue Procedures</td>
<td>C-1</td>
</tr>
<tr>
<td>D  Administrative Procedures - Reporting of Adverse Events</td>
<td>D-1</td>
</tr>
<tr>
<td>E  Other Administrative and Regulatory Procedures</td>
<td>E-1</td>
</tr>
<tr>
<td>F  Declaration of Helsinki</td>
<td>F-1</td>
</tr>
<tr>
<td>G  Case Report Forms</td>
<td>G-1</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

Clinical trials utilizing an experimental gingivitis study design have been frequently used as a short-term model with which to evaluate the antiplaque/antigingivitis efficacy of mouthrinses and were accepted by the FDA Plaque Products Subcommittee as a method of final formulation testing.

2. STUDY OBJECTIVES

The objective of this 2-week controlled clinical trial is to compare the antiplaque/antigingivitis efficacies of two Listerine Antiseptic mouthrinse formulations containing the identical fixed combination of four essential oils.

3. ETHICAL AND LEGAL CONSIDERATIONS\(^a\)

It is the responsibility of the investigator that this study be conducted in accordance with the Declaration of Helsinki, in accordance to the guidelines in the attached appendices, and in compliance with all applicable laws and regulations of the locale and country where the study is conducted.

It is the responsibility of the investigator to assure that this study be initiated only after the protocol and a copy of the informed consent document have been reviewed and approved by a duly constituted institutional review board (IRB) or ethics committee (EC), and all local institutional requirements are satisfied. Current regulations are summarized in Appendix E.

It is the responsibility of the investigator to ensure that each subject and/or his or her legal guardian (or caregiver) reads, understands, and signs a document of informed consent.

It is the responsibility of the investigator to inform the subject that personal information may be examined during audit or monitoring by properly authorized persons but that personal information will be treated as strictly confidential and not be made publicly available.

Indemnification of the investigator, coworkers, and the institution is provided as specified in the Clinical Study Agreement. For study centers outside the US and Canada, the

\(^a\) Appendices E, Other Administrative and Regulatory Procedures (Sections 1.1.2., IRB/EC Review and Approval of Study; 1.1.3., Subject Informed Consent; 1.6, Confidentiality of Subject Information; and 2.1, Information Required by Consumer Healthcare Research and Development for Regulatory Review) and F, The Declaration of Helsinki
current insurance policy number and coverage can be provided by the Consumer Healthcare Research and Development colleague(s) noted on the signature page of this protocol.

It is the responsibility of the investigator to retain the subject log and subject records as detailed in Appendix E.

4. STUDY DESIGN

This is a randomized, examiner-blind, parallel group, 2-week controlled clinical trial.

4.1 Target Population:
A sufficient number of qualifying subjects who have completed an informed consent form, a medical history, and an assessment of general oral health will be entered so that 150 subjects (50/group) could be reasonably expected to complete the study.

4.2 Screening Visit

Prior to the study initiation, each volunteer will be seen at the clinical site to obtain:

- informed consent
- medical history and subject screening
- assessment of general oral health and number of teeth (record on the subject screening form)

4.3 Admission

The prescreened subjects will present to the clinical site for baseline examinations having refrained from oral hygiene for at least 8 hours, but no more than 18 hours. Following the baseline examinations, qualifying subjects will receive a complete dental prophylaxis to remove plaque, stain and calculus (confirmed by use of disclosing solution). Subjects will begin their regimen of rinsing with their assigned mouthrinse for 30 seconds, twice daily for 2 weeks on the day of the prophylaxis.

5. STUDY POPULATION

5.1 Source and Number of Subjects

One hundred fifty (150) volunteers will be required to complete the study and must read and sign the Informed Consent Form after the nature of the study has been fully explained. Each subject will meet the following entrance criteria based on a pre-study screening.

Subjects will be selected by the investigator from a panel of subjects located in the area.
5.2. Subject-Selection Criteria

5.2.1. Inclusion Criteria

To be eligible for study participation, subjects must meet the following criteria:

1. Age range: 18 to 65 years

2. Gender: Males and females.

3. A minimum of 20 natural teeth with facial and lingual scorable surfaces. Teeth that are grossly carious, fully crowned or extensively restored on facial and/or lingual surfaces, orthodontically banded, abutments, or third molars will not be included in the tooth count.

4. A baseline gingival index (MGI [1]) score $\geq 1.95$.

5. A baseline plaque index (PI [2]) score $\geq 1.95$.

5.2.2. Exclusion Criteria

Any of the following conditions will exclude subjects from eligibility for study participation:

1. History of significant adverse effects following use of oral hygiene products such as toothpastes and mouthrinses.

2. History of diabetes or hepatic or renal disease, or other serious medical conditions or transmittable diseases, e.g. heart disease or AIDS.

3. History of rheumatic fever, heart murmur, mitral valve prolapse or other conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures.

4. Subjects on antibiotic, antiinflammatory or anticoagulant therapy during the month preceding the baseline exam.

5. Significant oral soft tissue pathology, excluding gingivitis, based on a visual examination.

6. Subjects known to be an alcoholic, or a recovering alcoholic.

7. Moderate/advanced periodontitis (ADA Type III, IV).

8. Gross dental caries, severe generalized cervical abrasion and/or enamel abrasion, large fractured or temporary restorations.
9. Fixed or removable orthodontic appliance or removable partial dentures.

10. Participation in a dental plaque/gingivitis clinical trial within the previous 30 days.

11. Self reported pregnancy or lactation (This is an exclusion criteria because oral tissue changes related to pregnancy and nursing can affect proper scoring of indices).

If the subject reports taking medication, a history of allergy, and/or a chronic disease, which in the opinion of dental examiner will not affect the clinical parameter(s) being assessed or the safety of the subject, the subject may be enrolled in the study and it will be noted on the Subject Screening Form.

5.3. Prohibited/Allowable Medications or Precautions

The use of any mouthrinse, dentifrice, or use of any oral hygiene devices other than the test materials is prohibited; a dental prophylaxis (other than the provided prophylaxis) during the study is also prohibited.

6. STUDY METHODOLOGY

6.1. Efficacy Assessments

Antiplaque/antigingivitis efficacy will be determined primarily by evaluation of the amount of supragingival dental plaque and of visual signs of marginal gingivitis, and secondarily by gingival bleeding determinations.

6.1.1. Primary Efficacy Parameter(s)

The primary efficacy variables are mean Modified Gingival Index [1] and mean Plaque Index [2] at 2 weeks.

6.1.2. Secondary Efficacy Parameter

The secondary efficacy variable is mean Gingival Bleeding Index [3] at 2 weeks.

6.2. Oral Tissue Assessments

Oral soft and hard tissue examinations will be conducted at each examination as described in Appendices B and C.

6.2.1. Adverse Event Reporting

b Appendix A. Timetable of Visits and Procedures
c Appendix B. Detailed Study Efficacy Procedures and Study Parameters Definitions
d Appendix C. Detailed Study Safety Procedures.
e Appendix D. Administrative Procedures for the Reporting of Adverse Event.
Observe and query each subject in a nonspecific fashion at each visit during the study for any new or continuing symptoms since the previous visit. Record this information as detailed in Appendix D.

### 6.2.1.1 Serious Adverse Events

Report immediately to Consumer Healthcare Research and Development any serious adverse event defined as any adverse event at any dose that results in any of the following outcomes:

- Death;
- Life-threatening adverse event;
- Inpatient hospitalization or prolongation of existing hospitalization;
- Persistent or significant disability/incapacity;
- Congenital anomaly/birth defect; or
- Medically significant event (includes laboratory abnormalities)

**IN CASE OF SERIOUS OR LIFE-THREATENING ADVERSE EVENTS, OR IN THE EVENT OF DEATH, A CONSUMER HEALTHCARE RESEARCH AND DEVELOPMENT COLLEAGUE MUST BE CONTACTED IMMEDIATELY.**

---

Michael L. Barnett, D.D.S.
Senior Director
Dental Affairs
170 Tabor Road
Morris Plains, NJ
Phone: (973-385-2254)
Home: (973-829-6966)

If any serious adverse event occurs, interrupt or discontinue study treatment at your (the physician investigator) discretion. If in acute medical emergency the Consumer Healthcare Research and Development colleague cannot be contacted, you may break the randomization code only if this is required for proper treatment of the subject. Notify the Consumer Healthcare Research and Development colleague of emergency code breaks as soon as possible.

### 6.2.1.2 Adverse Event Follow-up

In following up adverse events, attempts should be made to obtain as much information as possible about event evolution and outcome and maintain in subject file.

---

1. Appendix D, Administrative Procedures for Reporting of Adverse Events (Section 4.1, Immediately Reportable Adverse Events)
2. Appendix E, Other Administrative and Regulatory Procedures (Section 1.6, Emergency Information)
6.2.1.3 Other Safety Monitoring

Not Applicable

6.3. Removal of Subjects From the Study

Every effort within the bounds of safety and subject choice should be made to have each subject complete the study.

6.4. Study Completion

Following completion of the 2-week clinical examinations, subjects may brush their teeth and resume their usual oral hygiene and regular professional care. Subjects will receive a dental prophylaxis if they wish it.

7. STUDY TREATMENT

7.1. Description of Products:

The mouthrinses will be provided in subject specific bottles.

<table>
<thead>
<tr>
<th>PRODUCT NAME</th>
<th>DOSE REGIMEN</th>
<th>W/LH #</th>
</tr>
</thead>
<tbody>
<tr>
<td>FreshBurst Listerine with Fluoride</td>
<td>Rinse with 20 ml for 30 sec, bid</td>
<td>W2194-471</td>
</tr>
<tr>
<td>Listerine Antiseptic</td>
<td>Rinse with 20 ml for 30 sec, bid</td>
<td>W2194-377</td>
</tr>
<tr>
<td>5% Hydroalcohol Negative Control</td>
<td>Rinse with 20 ml for 30 sec, bid</td>
<td>W2194-221P</td>
</tr>
</tbody>
</table>

7.2. Blinding

The examiner will not know which of the treatments has been administered nor will the subject, the examiner, or the recorder have access to the treatment code. Personnel dispensing the test products or supervising their use will not participate in the examination of subjects in order to minimize potential bias.

The clinical study coordinator will receive one package containing 180 individual envelopes identified by subject number. Each numbered envelope will contain a mouthrinse formulation code and name and manufacturer's lot #. Identification of the product assigned to a subject may be revealed in the event of an adverse event. In such an instance, the investigator will, if circumstances and time permits, contact the study

---

h Appendix E, Other Administrative and Regulatory Procedures (Section 3.3, Study Termination)

i Appendix E (Code Breaks, Product Accountability)
monitor prior to breaking the code. The date and reason for such unblinding must be described on the appropriate case record form.

Subjects will be provided with a supply of their assigned test mouthrinse, 1 oz. plastic dosage cups marked at the 20 ml. level, and diaries in which to document weekend unsupervised rinse times.

7.3. **Regimen**

Following the baseline examination, a representative of the principal investigator will dispense the assigned mouthrinse and time the subject's rinsing. All subjects will be instructed not to rinse, eat or drink for 30 minutes after each mouthrinse use.

The two daily rinses Monday through Friday will be supervised. Each of the two rinses shall be separated by at least four hours. During the study, subjects will follow their usual dietary habits but will be instructed to refrain from using any oral care products other than the provided mouthrinse. The use of chewing gums and mints for the duration of the study is discouraged.

7.4. **Compliance and Return of Unused Supplies**

The test site will dispense individually coded bottles of mouthrinse for subject home use. The bottles will be returned to estimate compliance by measuring the volume of mouthrinse remaining at the end of each weekend.

The supply and return of the test products will be handled by the Consumer Healthcare Research and Development Clinical and Consumer Packaging Operations (CCPO) Department as named below.

Example: Attn: Carolyn Pusterla CCPO Dept.
Warner-Lambert
175 Tabor Road
Morris Plains, NJ 07950
Tel: 973-385-4389
Fax: 973-385-4383

8. **DATA COLLECTION**

Case Report Forms for Consumer Healthcare Research and Development or its designee will be supplied for all subjects. These are to be completed as instructed. Original source documents, CRF's, and other study documentation will be returned to Warner Lambert. Monitoring will be performed by a member of Consumer Healthcare Research and Development or its designee.

---

1. Appendix E, Other Administrative and Regulatory Procedures (Section 2.2, Guidelines for Recording Data in the Case Report Forms)
9. DATA ANALYSIS AND STATISTICAL CONSIDERATIONS

9.1 Data Analysis

9.1.1 Efficacy Variables

The primary efficacy variables are mean gingival index, as scored by the Modified Gingival Index [1], and mean plaque index, as scored by the Turesky modification of the Quigley-Hein Plaque Index [2], after 2 weeks of treatment.

The secondary efficacy variable is mean bleeding index, as scored by the Gingival Bleeding Index [3], after 2 weeks of treatment.

9.1.2 Data Sets Analyzed

Efficacy analysis will be based on evaluable subjects, defined as all randomized subjects with no major protocol violations. Demographic and baseline analyses will be performed both for all randomized subjects as well as for evaluable subjects.

9.1.3 Statistical Methodology

Data management and statistical analyses will be performed by the Statistics and Data Management Department at the Warner-Lambert Consumer Products Research & Development Division.

The three treatment groups will be compared with respect to age, baseline mean gingival index, baseline mean plaque index and baseline mean bleeding index by means of a one-way analysis of variance (ANOVA) model with treatment as a factor, and with respect to race, gender and smoking status by means of a chi-square test.

The 2-week data for mean gingival index, mean plaque index and mean bleeding index will be analyzed using a one-way analysis of covariance (ANCOVA) model with treatment as a factor and the corresponding baseline value as a covariate. The baseline-by-treatment interaction will be examined to assess the homogeneity of slopes.

The following three pairwise comparisons will be tested:

a. Listerine Antiseptic versus 5% hydroalcohol control mouthrinse

b. Freshburst Listerine with fluoride versus 5% hydroalcohol control mouthrinse

c. Freshburst Listerine with fluoride versus Listerine Antiseptic

---

1 Appendix E, Other Administrative and Regulatory Procedures (Section 2.2, Guidelines for Recording Data in the Case Report Forms)
The comparative criteria established to demonstrate acceptable performance for the test product are twofold:

1. The test product has to be statistically significantly superior to the control for each of the primary efficacy variables;

2. The test product has to be "at least as good as" [4] the positive control (Listerine Antiseptic). This criterion will be met for the test product if, for each of the primary efficacy variables, the upper limit of the one-sided 95% confidence interval for the difference between the test and positive control means (expressed as a percentage difference relative to positive control) is below 10%.

The study will be considered validated if the post-treatment means of the primary efficacy variables for Listerine Antiseptic are statistically significantly lower than the corresponding means of the 5% hydroalcohol control mouthrinse.

For each efficacy variable, within treatment comparisons will be performed on the change from baseline after 2 weeks of treatment by means of a paired t-test.

Summary statistics will be provided for mean gingival index, mean plaque index and mean bleeding index by treatment group at baseline and after 2 weeks of treatment.

Safety data will be summarized by treatment group.

9.2. Statistical Power and Sample Size Considerations

The total sample size of 150 (50 per group) completed, evaluable subjects is based on estimates of variability and adjusted means from studies #1207, #1214, #1223, #1251, #1272, #1281, and #1303. This sample size should provide at least 80% probability that the upper 95% confidence limit for the difference between means for Freshburst Listerine with fluoride and Listerine Antiseptic is less than 10% of the Listerine Antiseptic mean. This assumes that the underlying mean is no more than 2.5% higher for Freshburst Listerine with fluoride than for Listerine Antiseptic, and that the coefficient of variation (c.v.) is 14% for mean Modified Gingival Index and 15% for mean Plaque Index. The c.v. of 14% is the largest c.v. for mean Modified Gingival Index observed in the seven studies; while 15% is the average of the c.v.'s for mean Plaque Index in these studies.

9.3. Oral Tissue Parameters

Oral tissue findings will be summarized in tabular form in the final study report.

10. REFERENCES


11. LIST OF APPENDICES

A. Timetable of Visits and Procedures
B. Detailed Study Efficacy Procedures and Study Parameter Definitions
C. Detailed Oral Tissue Procedures
D. Administrative Procedures for the Reporting of Adverse Events
E. Other Administrative and Regulatory Procedures
F. Declaration of Helsinki
G. Case Report Forms
## APPENDIX A

### TIMETABLE OF VISITS AND PROCEDURES

<table>
<thead>
<tr>
<th>TIME</th>
<th>EVENT</th>
<th>PROCEDURES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to Day 1</td>
<td>Screening</td>
<td>Informed Consent, oral exam for # of teeth, presence of gingivitis and supragingival dental plaque.</td>
</tr>
<tr>
<td>Day 1</td>
<td>Baseline</td>
<td>Qualifying exams, dental prophylaxis, product dispensing, instruction, and supervised use.</td>
</tr>
<tr>
<td>Days 1-5*</td>
<td>Weekday supervised rinsing</td>
<td>Twice daily rinsing and recording by rinsing supervisor.</td>
</tr>
<tr>
<td>Days 8-12*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days 6-7*</td>
<td>Unsupervised rinsing</td>
<td>Twice daily unsupervised rinsing and diary recording.</td>
</tr>
<tr>
<td>Days 13-14*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 15</td>
<td>Clinical Evaluations</td>
<td>2-week final clinical exams (soft tissue, gingivitis, bleeding and plaque)</td>
</tr>
</tbody>
</table>

Note: the Days will vary depending on the day of the week subject enters the study.
APPENDIX B

Detailed Study Efficacy Procedures and Study Parameter Definitions

Clinical Evaluations:

All examinations will be performed by a trained dental examiner. Prior to initiation of exams, the examiner will review the indices with a representative of the sponsor. The examiner will call out his findings to the recorder who will enter the findings on the appropriate paper case report forms. The examiner(s) will not have access to the case report forms until the completion of the examinations.

Subjects will refrain from oral hygiene for at least 8 hours, but no more than 18 hours, on the day of the baseline examinations and will additionally refrain from use of test products for at least 4 hours prior to the examinations at 2 weeks. Separate case report forms (Appendix G) will be used at each examination.

Case report forms will be submitted to the sponsor after completion of each examination period. Copies of the case report forms will be retained by the investigator.

The order of clinical examinations will be oral soft and hard tissue assessment, Modified Gingival Index, Bleeding Index, and Plaque Index.

Oral Tissue Assessment: Buccal, labial and sublingual mucosae, tongue, hard and soft palate, uvula and oropharynx, and teeth will be examined at baseline and 2 weeks. Aberrations will be recorded, their severity assessed and a judgment made as to whether they can be attributable to the test materials.

Gingivitis will be scored at baseline and 2 weeks by the Modified Gingival Index [1] on the buccal and lingual marginal gingivae and interdental papillae of all scorable teeth:

0 - Normal (absence of inflammation).
1 - mild inflammation (slight change in color, little change in texture) of any portion of the gingival unit.
2 - mild inflammation of the entire gingival unit.
3 - moderate inflammation (moderate glazing, redness, edema, and/or hypertrophy) of the gingival unit.
4 - severe inflammation (marked redness and edema/hypertrophy, spontaneous bleeding, or ulceration) of the gingival unit.

Bleeding will be assessed at baseline and 2 weeks according to the Gingival Bleeding Index as defined by Saxton and van der Ouderaa [3] A periodontal probe, (Quix™ Color Coded Probe PCPILSB, Hu-Friedy Mfg. Co., Inc., Chicago, IL 60618) with a 0.5 mm diameter tip inserted into the gingival crevice, will be swept from distal to mesial around
the tooth at a depth of approximately 1 mm. and at an angle of approximately 60° while in contact with the sulcular epithelium. Each of 4 gingival areas (disto-buccal, midbuccal, mesio-buccal and mid-lingual) around each tooth will be assessed in this manner waiting approximately 30 seconds before recording the number of gingival units which bleed, according to the following scale:

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>absence of bleeding after 30 seconds</td>
</tr>
<tr>
<td>1</td>
<td>bleeding observed after 30 seconds</td>
</tr>
<tr>
<td>2</td>
<td>immediate bleeding observed</td>
</tr>
</tbody>
</table>

Plaque area will be scored at baseline and at 2 weeks by the Turesky modification of the Quigley-Hein Plaque Index [2], on the buccal and lingual surfaces of all scorabie teeth, following disclosing:

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>no plaque.</td>
</tr>
<tr>
<td>1</td>
<td>separate flecks or discontinuous band of plaque at the gingival (cervical) margin.</td>
</tr>
<tr>
<td>2</td>
<td>thin (up to 1 mm), continuous band of plaque at the gingival margin.</td>
</tr>
<tr>
<td>3</td>
<td>band of plaque wider than 1 mm but less than 1/3 of surface.</td>
</tr>
<tr>
<td>4</td>
<td>plaque covering 1/3 or more, but less than 2/3 of surface.</td>
</tr>
<tr>
<td>5</td>
<td>plaque covering 2/3 or more of surface.</td>
</tr>
</tbody>
</table>
APPENDIX C

Detailed Oral Tissue Assessment Procedures

Oral Tissue Assessment: Buccal, labial and sublingual mucosae, tongue, hard and soft palate, uvula and oropharynx, and teeth will be examined at baseline and all subsequent visits. Pathoses observed at baseline will be recorded. Any change from baseline and any new pathology will then be noted at subsequent visits, severity assessed, and a judgment made as to whether the new finding can be attributed to the test materials.

An expected outcome for some subjects may be a transient tingling or burning sensation on the oral soft tissues, which has been reported with use of essential oil-containing products. If there is no associated clinical pathology in subjects reporting this sensation, then it will not be considered an adverse event and the comment will be captured by the subject on his/her diary, and/or as a comment on a clinical CRF. All other oral complaints require a clinical evaluation and diagnosis and should be recorded as an adverse event.

Follow-up will be conducted until the tissue returns to normal or up to 30 days following the completion of the study.

ORAL TISSUE EXAMINATION

The following terminology and examples are provided to enhance consistency in recording adverse product effects as well as other soft tissue pathology and deviations from the normal on the oral tissue examination form.

I. Terminology to describe pathoses

A. Physical Form

1. ulcer
2. vesicle/bulla
3. plaque
4. macule/papule
5. color
6. leukoplakia
7. edema/edematous
8. erosion/erosive
9. desquamation/desquamative
B. Location

1. dorsal
2. ventral
3. lateral
4. buccal, lingual, palatal, labial
5. tonsillar, pharyngeal
4. anterior, middle, posterior
5. papillary
6. marginal
7. generalized
8. localized (well circumscribed, solitary)

II. Examples of product related effects reported in the literature:

1. Plasma cell gingivitis (response to cinnamon)
2. Pigmentation
3. Erythema
4. Edema - tongue, gingiva, labial mucosa, etc.
5. Parotitis
6. Vesicles
7. Ulceration
8. Coated tongue
9. Burning or itching
10. Tooth erosion
11. Tooth staining
12. Glossitis
13. Stomatitis
14. Necrosis
15. Loss of lingual papillae
16. Epithelial desquamation
17. Angular cheilitis
III. Common pathoses not product-related (record for baseline documentation to differentiate from product-related lesions)

A. Red lesions and ulcerations

1. Traumatic ulcers
2. Traumatic erythematous macules
3. Purpuric macules
4. Migratory glossitis and stomatitis
5. Recurrent aphthous stomatitis
6. Recurrent herpetic stomatitis
7. Erosive lichen planus
8. Atrophic candidiasis
9. Desquamative gingivitis
10. Erythroplakia
11. Candidiasis
12. ANUG (Acute Necrotizing Ulcerative Gingivitis)
13. NUP (Necrotizing Ulcerative Periodontitis)

B. White Lesions

1. Hyperkeratosis
2. Lichenoid stomatitis [histology required for lichen planus]
3. Candidiasis
4. Chemical burns - aspirin, etc
5. Leukoplakia (WHO definition)
6. Traumatic Ulcer
7. Leukoedema

C. Miscellaneous pathoses

1. Gingivitis
2. Parotitis
3. Vesicles
4. Ulceration
5. Coated tongue
6. Burning or itching
7. Erosion (teeth)
8. Glossitis
9. Epithelial desquamation
10. Angular cheilitis
11. Cheek or lip biting
12. Fibroma
13. Papilloma
14. Pyogenic granuloma
15. Scars
16. Mucocle
17. Fistula (parulis)
18. Periodontitis
19. Linea alba
20. Racial pigmentation
21. Amalgam tattoo
22. Palatal Tori/mandibular tori
23. Lingual varicosities
24. Exostoses
25. Geographic tongue
26. Fissured tongue

IV. Record only if abnormal

Tonsils
Lymphoid tissue
Fissured tongue
APPENDIX D

Administrative Procedures for the Reporting of Adverse Events

INTRODUCTION

The administrative procedures for reporting adverse events described in this appendix are to be followed during the conduct of this protocol.

If you have any questions concerning adverse event reporting, please contact the Consumer Healthcare Research and Development colleague or representative who is monitoring your site or a Consumer Healthcare Research and Development colleague whose name, address, and telephone number appears on the cover sheet to this protocol.
TABLE OF CONTENTS

1. ADVERSE EVENTS DURING THE STUDY .......................................................... D-3
2. DEFINITIONS ................................................................................................. D-3
   Pre-existing conditions .................................................................................. D-3
   Baseline .......................................................................................................... D-3
   Adverse Event ................................................................................................. D-3
   Related Adverse Event .................................................................................... D-3
   Serious Adverse Events (SAE) ........................................................................ D-3
   Life Threatening Adverse Event ..................................................................... D-4
   Unexpected Adverse Event ............................................................................ D-4
   Clinical Laboratory Adverse Event ............................................................... D-4
   Treatment-Emergent Signs and Symptoms (TESS) ......................................... D-5
   Post-treatment Adverse Event ....................................................................... D-5
   Lack of Efficacy .............................................................................................. D-5

2.1. Attributes of Adverse Events ...................................................................... D-5
   2.1.1 Treatment-Emergent Signs and Symptoms (TESS) ........................... D-5
   2.1.2 Serious Adverse Events ...................................................................... D-5
   2.1.3. Intensity ............................................................................................. D-5
   2.1.4. Relationship to Study Drug - Physician's Assessment ..................... D-6
   2.1.5. Clinical Outcome .............................................................................. D-6

3. CAPTURING ADVERSE EVENTS ................................................................. D-7
   3.1. Pre-Exiting Conditions ........................................................................... D-7
   3.2. Lack of Efficacy ...................................................................................... D-7
   3.3. Clinical Laboratory Adverse Events ....................................................... D-7
   3.4. Hospitalization or Surgery/Procedures .................................................. D-7
   3.5. Death ....................................................................................................... D-7
   3.6. General Physical Examination Findings ............................................... D-8

4. RECORDING AND REPORTING ................................................................. D-8
   4.1. Immediately Reportable Adverse Events .............................................. D-9
   4.2. Other Adverse Events ............................................................................ D-9
   4.3 Follow-Up Period .................................................................................... D-9
1. **ADVERSE EVENTS DURING THE STUDY**

Each subject will be observed and queried in a nonspecific fashion by the investigator or study coordinator at each visit during baseline, study treatment, and protocol-defined follow-up for any new or continuing adverse events (AEs) since the previous visit. Any new AEs or ones changing in character, frequency, or in intensity reported by the subject or caregiver or noted by the investigator or study coordinator after the signing of the informed consent will be recorded on the AE Case Report Form (CRF).

The investigator will review any clinical laboratory test results in a timely fashion when received from the laboratory. Those results qualifying as AEs as defined in Sections 2 of Appendix D. This appendix will be recorded on the AE CRF and will be handled according to these administrative procedures for reporting AEs.

The investigator will review concomitant medications being taken by the subject. The AE that led to the administration of any new concomitant medications (not specified in the protocol) will be reported on the AE CRF.

2. **DEFINITIONS**

**Pre-Existing Conditions**

A pre-existing condition is one that is present at the start of study treatment.

**Baseline**

Defined by the Therapeutic Group for each program.

**Adverse Event**

Any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

**Related Adverse Event**

An AE where there is a reasonable possibility that the event may have been caused by drug (Unknown is also considered related).

**Serious Adverse Event (SAE)**

Any adverse event occurring at any dose that results in any of the following outcomes:

- Death;
Life-threatening adverse event;
- In subject hospitalization or prolongation of existing hospitalization;
- Persistent or significant disability/incapacity;
- Congenital anomaly/birth defect; and
- Medically significant event (includes laboratory abnormalities).

Medically significant events may not be immediately life threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the outcomes listed in the definition above. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or development of drug dependency or drug abuse, or laboratory abnormalities.

The following hospitalizations are not considered SAEs:
- For diagnostic or elective surgical procedures for a pre-existing condition;
- For therapy of the target disease(s) of the study if the protocol explicitly anticipated and defined the symptoms or episodes;
- For study efficacy measurement, as defined in the protocol.

Life-Threatening Adverse Event

Any adverse event that places the subject or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Unexpected Adverse Event

Any adverse event, the specificity or severity of which is not consistent with the current Investigator's Brochure. For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the Investigator's Brochure only referred to elevated hepatic enzymes or hepatitis.

Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the Investigator's Brochure only listed cerebral vascular accidents. "Unexpected," as used in this definition, refers to an AE that has not been previously observed (e.g., included in the Investigator's Brochure) rather than from the perspective of such experience not being anticipated from the pharmacological properties of the product.

Clinical Laboratory Adverse Event

A clinical laboratory abnormality that is regarded as an AE if it has been confirmed by at least 1 repeat test and suggests a disease and/or organ toxicity of a severity that requires
active management, e.g., change of dose, discontinuation of drug, more frequent follow-up, diagnostic investigation, etc.

**Treatment-Emergent Signs and Symptoms (TESS)**

Any AE that was not evident during baseline as defined by the study protocol or that increases in intensity or frequency, or changes in character during treatment.

**Post-Treatment Adverse Event**

Any AE that occurs after study treatment is discontinued. Post-treatment follow-up and post-treatment adverse events of interest to the study will be defined per protocol.

**Lack of Efficacy**

A worsening of the disease being studied or lack of desired effect of the study drug (not reported as an AE if defined as an efficacy parameter in the protocol).

2.1. **Attributes of Adverse Events**

2.1.1. **Treatment-Emergent Signs and Symptoms (TESS)**

Any condition/diagnosis that meets the definition of a TESS event is captured as such on the AE CRF.

2.1.2. **Serious Adverse Events**

All SAEs, as defined in Section 2, are immediately reportable to the Sponsor within 24 hours of the Investigator’s first knowledge of the event (see Section 4.1 of this appendix).

If there is an exception to the SAE definition, it is described in the protocol.

2.1.3. **Intensity**

The following criteria are used to assess the intensity of each AE:

*Mild:* The subject is aware of the sign or symptom, but finds it easily tolerated.

*Moderate:* The subject has discomfort enough to cause interference with or change usual activities.

*Severe:* The subject is incapacitated and unable to work or participate in many or all usual activities.
2.1.4. Relationship to Study Drug—Physician’s Assessment

Causality will be captured by the investigator on the CRF Adverse Events as one of the following choices:

(a) Probable
A clinical event, including a laboratory test abnormality, which meets all of the following criteria:

i. Occurs within a reasonable time sequence to administration of the drug.
ii. Is unlikely to be attributed to concurrent disease or other drugs or chemicals.
iii. There is a positive dechallenge; that is, the event follows a clinically reasonable response on withdrawal.
iv. Rechallenge information is not required, or may be unclear or not applicable. However, if the information is available, rechallenge is positive; that is, the event recurs upon reintroduction.

(b) Possible
A clinical event, including a laboratory test abnormality, which meets all of the following criteria:

i. Occurs within a reasonable time sequence to administration of the drug.
ii. Could also be explained by the presence of concurrent disease or other drugs or chemicals.
iii. Dechallenge information is not required, or may be unclear or not applicable. However, if the information is available, dechallenge may be positive or negative; that is, the event may or may not follow a clinically reasonable response on withdrawal.
iv. Rechallenge information is not required, or may be unclear or not applicable. However, if the information is available, rechallenge may be positive or negative; that is, the event may or may not recur upon reintroduction.

(c) Unlikely
A clinical event, including a laboratory test abnormality, which meets one of the following criteria:

i. The temporal relationship (time sequence to drug administration) makes a causal relationship improbable or
ii. Other drugs, chemicals, underlying disease, or other factors provide more plausible explanations.

2.1.5. Clinical Outcome

The following categories are used to assess the clinical outcome of each AE:

Recovered (with or without residual effects):
Appendix D  
Protocol #931-1309  
May 9, 2000

The subject has fully recovered from the AE with or without observable residual effects.

Not Yet Recovered:

The subject is still being treated for the residual effects of the original AE. This does not include treatment for pre-existing conditions including the indication for the study drug.

Died Due to This Adverse Event

Died, Other Causes

Unknown

Surgery/Procedure

3. CAPTURING ADVERSE EVENTS

3.1. Pre-Existing Condition

A pre-existing condition should be reported as an AE if the frequency, intensity, or the character of the condition worsens during study treatment.

3.2. Lack of Efficacy

Signs or symptoms defined in the protocol as lack of efficacy or collected as efficacy parameters should not be reported as AEs.

3.3. Clinical Laboratory Adverse Event

A clinical laboratory abnormality should be reported as an AE only if the conditions are met as defined in Section 2.

3.4. Hospitalization or Surgery/Procedure

Any AE that results in hospitalization (i.e., subject admitted—not just an emergency room visit) should be reported as an SAE except as described in Section 2 of Appendix D or unless specifically instructed otherwise in the protocol. Any condition/diagnosis responsible for surgery/procedure should be reported as an AE if it meets the criteria for an AE. The surgery/procedure itself will be reported as a Clinical Outcome of the underlying event.

Events that prolong any hospitalization are reported as SAEs.

3.5. Death

The cause of death should be reported as an AE. Death should not be reported as an AE, but as a Clinical Outcome. The only exception is “Sudden Death” when the cause of death is unknown, which is reported as an AE with death as the Clinical Outcome.
3.6. **General Physical Examination Findings**

At screening, any clinically significant finding should be recorded on the General Medical History CRF. After the signing of the informed consent document, any new clinically significant finding that meets the definition of an AE must be documented as such.

4. **RECORDING AND REPORTING**

All AEs that occur at any time during the study including the posttreatment period as defined in the protocol, are to be reported in the subject’s CRFs. The investigator should attempt, if possible, to establish a diagnosis based on the presenting signs and symptoms.

If the event meets the definition of a “serious” adverse event, a photocopy or fax of the Warner-Lambert Serious Adverse Event Report, the Adverse Event Case Report Form, and Concomitant Medication Case Report Form, and/or other pertinent information must be provided within 24-hours to the clinical monitors. Warner-Lambert Company will monitor the completeness and accuracy of these forms.

At each visit, after the subject has had an opportunity to spontaneously mention any problems, the investigator should inquire about adverse events by asking the following standard questions:

a. “Have you had any (other) medical problems since your last visit?”

b. “Have you taken any new medications, other than those given to you in this study, since your last visit?”

All unresolved adverse events observed at the last study visit should be followed by the investigator until the events are resolved, stabilized, the subject is lost to follow-up, or the events are otherwise explained. All follow-up information should be reported to Warner-Lambert Company.

Adverse events will be recorded at each clinic visit. All adverse events should be recorded on the Adverse Events page of the Case Report Form including date of onset and cessation, intensity and relationship to study drug. The action taken and clinical outcome of SERIOUS adverse events must be reported to the Clinical Monitor without delay. All medical problems occurring since the previous visit which were not present at the initial must be recorded. If there is worsening of a medical condition that was present at the initial visit, this should also be reported. This information is obtained by questioning the subject and/or caregiver and/or examining the subject.
Appendix D
Protocol #931-1309
May 9, 2000

4.1. Immediately Reportable Adverse Events

The investigator or designee must report the occurrence of any serious adverse event to the Warner-Lambert Company within 24 hours, regardless of the causal assessment to study medication, and followed up with a detailed written explanation of the event within 3 days.

A photocopy or fax of the Warner-Lambert Serious Adverse Event Report, the Adverse Event Case Report Form, and Concomitant Medication Case Report Form, and/or other pertinent information must be provided within 24-hours to:

Dr. Michael Barnett  
Dental Affairs/Technology Development  
Consumer Healthcare R & D  
Warner-Lambert Company  
170 Tabor Road  
Morris Plains, NJ 07950  
Tel: (973-385-2254)  
Fax: (973-540-4400)

The investigator is responsible for continuing to report to Warner-Lambert Company, within 24 hours, any new or relevant follow-up information on the serious adverse event as the information becomes known to the investigator. All unresolved serious adverse events should be followed by the investigator until the event has resolved, stabilized, the subject is lost to follow-up, or the event is otherwise explained.

4.2. Other Adverse Events

AEs that are not immediately reportable according to the definitions in this appendix will only be recorded on the standard AE CRF. These forms will be collected by the sponsor after the event is resolved, or if the event is continuing, at approximately 12- to 16-week intervals until after the AE ends or if the AE does not end, until the subject completes the study or the protocol-specified follow-up period.

4.3. Follow-Up Period

For SAEs, the subject must remain under observation until the SAE has subsided or stabilized and all serious pathological values and findings have returned to normal or stabilized.

Follow-up information will not be collected for "not yet recovered" or continuing nonserious AEs unless time frames are specifically written in the protocol.
APPENDIX E

Other Administrative and Regulatory Procedures

INTRODUCTION

This appendix provides information necessary to administer this study in compliance with global
GCPs, government regulations, and the policy and procedures of Consumer Healthcare Research

If you have any questions concerning the conduct of the study, contact one of the Consumer
Healthcare Research and Development Dental Affairs Colleagues whose name, address, and
telephone number appears on the signature sheet to this protocol.

Your signature on this cover page of the protocol, any subsequent amendments and addenda, and
the Clinical Study Agreement confirms that you:

- Have been given appropriate information on the study drug;
- Have read and understood the protocol and appendices;
- Agree to conduct the study in accordance with the provisions of the protocol and applicable
  regulations;
- Acknowledge Consumer Healthcare Research and Development' ownership of the data and
  results obtained from the conduct of this protocol; and
  - Agree to maintain the confidentiality of certain information (see Section 1.8.1)
1. Administrative Procedures

1.1. Ethics and Informed Consent
1.1.2 Institutional Review Board (IRB) or Ethics Committee (EC) Review and Approval of the Study
1.1.3. Subject Informed Consent

1.2. Clinical Evaluations Not Specified in the Protocol

1.3. Monitoring the Study
1.3.1. Prestudy Visit
1.3.2. Investigators' Meeting
1.3.3. Study Initiation Visit
1.3.4. Monitor Visits and Phone Contacts
1.3.4.1. Source Data Verification
1.3.5. End-of-Study Visit
1.3.6. Communicating Deficiencies

1.4. Randomization Code
1.5. Medical Intervention and Code Breaking
1.6. Confidentiality of Subject Information
1.7. Publication or Presentation of Results
1.7.1. Intellectual Property Rights

1.8 Restriction for Subject Inclusion

2. DOCUMENTATION PROCEDURES

2.1. Information Required by Consumer Healthcare Research and Development for Regulatory Review
2.1.1 Prior to Study Initiation
2.1.1.1. New Product Application (IND)
2.1.1.2. Non-IND Application
2.1.2 During the Study
2.1.3 End of Study

2.2. Guidelines for Recording Data in the Case Report Forms

2.3. Review of Case Report Forms

2.4. Investigator's Responsibility for Clinical Product Supply Accountability
2.4.1. Receipt of Clinical Product Supplies
2.4.2. Storage
2.4.3. Dispensing of Clinical Product Supplies
2.4.4. Return of Clinical Product Supplies

3. PROTOCOL AMENDMENTS AND ADDENDA

3.1. Urgent Protocol Amendment
3.2. Other Amendments
3.3. Study Termination
3.4. Deviations from Protocol
1. ADMINISTRATIVE PROCEDURES

1.1. Ethics and Informed Consent

Declaration of Helsinki

This study will be conducted in accordance with the Declaration of Helsinki.

1.1.2. Institutional Review Board (IRB) or Ethics Committee (EC) Review and Approval of the Study

An IRB/EC, that is organized and operates according to GCP and applicable laws and regulations, should safeguard the rights, safety, and well being of all trial subjects. No subject should be admitted to a trial before the IRB/EC issues its written approval/favorable opinion of the trial.

The investigator is responsible for:

- Promptly reporting to the IRB/EC all changes in the research activity, and all unanticipated problems involving risks to human subjects or others;
- Not making any changes in the research without IRB/EC approval, except when absolutely necessary to eliminate apparent immediate hazards to human subjects;
- Submitting a progress report describing the status of the clinical investigation to the IRB/EC at appropriate intervals not exceeding 1 year, and
- Submitting a final report when required by the IRB/EC within 3 months following completion, termination, or discontinuation of the study. Copies of these reports will also be provided to Consumer Healthcare Research and Development.

In general, all communications with the IRB/EC regarding the study of a Consumer Healthcare Research and Development drug will be handled by the principal investigator (or coordinating investigator, if applicable) of the study. Consumer Healthcare Research and Development personnel may directly contact the IRB/EC if necessary but must not attempt to influence the IRB/EC in any way. A copy of all communications from the IRB/EC to the investigator regarding its review of and initial approval of the study and its reapprovals at intervals must be provided to the Consumer Healthcare Research and Development Site Monitor/Clinical Research Associate by the investigator.

1.1.3. Subject Informed Consent

The investigator must fully explain the purpose of the study to the subject or his/her guardian prior to entering the subject into the study. The investigator is responsible for obtaining written informed consent from each subject. For subjects under the legal age of consent or unable to provide written consent, written informed consent must be obtained from his/her legal guardian, or legal representative. Also, the assent of a child to participate in the study must be obtained when appropriate, e.g., in consideration of the child’s age and maturity.
Consumer Healthcare Research and Development requires that informed consent be obtained orally and on a written form prepared by the investigator and approved by the IRB/EC. Although a sample Informed Consent Document (ICD) may be provided to international investigators or a template to US investigators, the investigator is ultimately responsible for the content of the document.

The person signing the consent form will receive a copy of the signed form. The signed consent form will be filed at the site with the investigator's copies of the Case Report Forms (CRFs) for each subject.

1.2. Clinical Evaluations Not Specified in the Protocol

Procedures not specified in the protocol can be conducted only if required for the successful management of a subject or they will not affect the conduct or results of the study and each procedure should be approved by the Consumer Healthcare Research and Development Medical/Dental Colleague.

1.3. Monitoring the Study

Frequent contact between the principal investigator and Consumer Healthcare Research and Development will be maintained by the Medical/Dental Colleague and/or the Site Monitor/Clinical Research Associate, or comparable persons from a designated Contract Research Organization appointed by Consumer Healthcare Research and Development, to assure that this study is conducted according to the protocol and that all forms are accurate and complete prior to being forwarded to Consumer Healthcare Research and Development.

1.3.1. Prestudy Visit

Representatives from Consumer Healthcare Research and Development, usually those who will monitor the site, will visit the investigator, site staff, and study facility prior to initiation of the clinical study to:

Review the key elements of the available information on the investigational drug and the protocol;

Determine the site's ability to conduct the study based on, for example, experience, adequacy of physical facilities;

Assess availability of an adequate, suitable subject population; and

Assess IRB/EC involvement and accessibility for Site Monitor/Clinical Research Associate visits including source document verification against medical records.

If the prospective investigator has conducted a study for the Company within the last 12 months with the same investigational drug, a telephone interview may be used to replace an on-site visit at the discretion of the Senior Director.
1.3.2. Investigators' Meeting

Principal investigators must not enroll subjects into a study unless they have received training on all aspects of a clinical study. For multicenter studies, this training is typically provided at an Investigators' Meeting. A prestudy Investigators' meeting is a formal meeting between the sponsor and the investigators and their staff to review all aspects of a clinical study prior to study initiation. The main purposes of this meeting is to:

- Review the study protocol and procedures;
- Resolve any questions regarding the purpose(s) and conduct of the study;
- Instruct all participants in the administrative and regulatory (i.e., GCP) procedures to be followed.

For some studies, the Senior Director may waive the Investigators' Meetings if the goals have been accomplished via a Prestudy Visit and/or Investigators' Meeting or the site has participated in other similar studies for Consumer Healthcare Research and Development within the past 12 months.

1.3.3. Study Initiation Visit

This visit, which is conducted by the Site Monitor/Clinical Research Associate, typically occurs after the Investigators' Meeting and after written study materials and clinical supplies are at the site, and before subject enrollment. The purpose of this visit is to ensure that both Consumer Healthcare Research and Development and the investigator have fulfilled all necessary obligations before treating subjects in a clinical trial. During the visit, the Site Monitor/Clinical Research Associate reviews with the investigator and appropriate site staff the key elements of study documents and supplies and their study obligations and roles.

1.3.4. Monitoring Visits and Phone Contacts

Routine monitoring visits, at appropriate intervals detailed in the monitoring guidelines, will be scheduled based on the design and complexity of the protocol and the timelines for obtaining study results to:

- Verify that the rights and well-being of human subjects are protected (e.g., signed informed consent document, IRB/EC approvals, etc);
- Ensure study conduct in accordance with the protocol (and any amendments), local regulatory requirements, Consumer Healthcare Research and Development procedures, and GCPs;
 Verify the accuracy and timely ensure completion of the recorded data (e.g., CRFs) with respect to source documents (see Section 1.3.4.1 below);

- Resolve data queries;
- Verify that data and biological samples are collected in a timely manner;
- Maintain an accurate record of study progress;
- Account accurately for clinical drug supplies;
- Ensure continued acceptability of facilities for study conduct;
- Ensure appropriate maintenance of required documents;
- Prepare the site for audits.

In addition, both Consumer Healthcare Research and Development and the site are responsible for documenting substantive telephone conversations (e.g., those about inclusion/exclusion criteria in the protocol, medication dosing procedures, adverse events, and emergency code breaks).

1.3.4.1. Source Data Verification

The purpose of Source Data Verification (SDV; also known as Source Document Verification) is to ensure as much as possible the accuracy, quality, and reality of the data recorded on CRFs via a comparison to source documents. Source documents are the original documents or records where raw/source data concerning a subject have been first recorded, e.g., medical charts, hospital records, clinical laboratory reports, X-rays, automated instrument tracings, signed and dated informed consent documents.

1.3.5. End-of-Study Visit

The final on-Site Monitor visit is conducted when:

- The investigator completes the study or requests to discontinue participation in the study; or
- Consumer Healthcare Research and Development decides to discontinue the study for all investigators in a trial (e.g., due to adverse events or study enrollment being reached) or for an individual investigator (e.g., due to poor subject enrollment).

Purposes of the End-of-Study Visit include:

- Reviewing and ensuring completeness of required documentation and documentation retention policies;
- Collecting completed CRFs;
• Ensuring that all adverse events have been identified, documented and reported to Warner Lambert;
• Ensuring final returning/disposition of any remaining clinical drug supplies;
• Ensuring that the investigator has notified the IRB/EC of study completion or discontinuation;
• Reviewing processes that occur after the End-of-Study Visit; and
• Finalizing payment issues.

1.3.6. Communicating Deficiencies

The Consumer Healthcare Research and Development Site Monitor/Clinical Research Associate will inform the site of any deficiencies related to the conduct of the study noted during monitoring visits or audits conducted by Consumer Healthcare Research and Development QA colleagues.

1.4 Randomization Code

The Statistics and Data Management Department of Consumer Healthcare Research and Development or designee generates the randomization code, and then Consumer Healthcare Research and Development or other designated facility will provide product assembled for each subject based on the randomization code.

1.5. Medical Intervention and Code Breaking

If any adverse event requires medical intervention, the study medication may be discontinued and the subject treated at the discretion of the physician investigator. In an acute medical emergency, the product assignment code may be broken if this is considered essential for subject management. For this purpose, the product assignment code will be provided to the investigator in a sealed envelope. However, before breaking the code, an attempt must be made to contact the Warner-Lambert Monitor. If not possible, contact should be made at the first opportunity. If the code is broken, a record of the time and reason must be put in writing and sent to the Warner-Lambert Monitor. This letter will become part of the permanent study record. The investigator’s copy of the sealed product assignment code must be returned to Warner-Lambert at the end of the study.

1.6. Confidentiality of Subject Information

All subjects will be assigned a study subject number. Subsequently, subjects will be identified in the CRFs only by their initials and that number. Any information published as a result of the study will be such that it will not permit identification of any subject. The information from this study will be available within Consumer Healthcare Research and Development and may be shared with the regulatory authorities. It may also be the subject of an audit by a regulatory agency (e.g., FDA) within the local government. The subject’s identity will remain protected except as required for legal or regulatory inquiries.
1.7. Publication or Presentation of Results

Upon written permission from Warner-Lambert, the investigator shall be free to publish, present or use any results arising out of the performance of the study for their own instructional, research or publication objectives. Any proposed oral or written use of such results by the investigator shall be submitted to Warner-Lambert for review at least forty-five (45) days prior to submission for publication, presentation or use. This condition is stated so that Warner-Lambert will be aware of all written and oral presentations of the data and does not imply any editorial review or restriction of the contents of the presentation or use.

Warner-Lambert shall reserve the right to deny publication or presentation of the data or to request modification of any publication, presentation or use of study results if such publication, presentation or use will jeopardize a patent application or patent. If the investigator does not consent to such modification, independent patent counsel will be consulted at Warner-Lambert’s option; provided that the decision of such patent counsel shall serve only as guidance to, and shall not be binding upon, the investigator.

Further, if there are medical reasons justifying submission for publication, presentation or use sooner than 45 days after submission to Warner-Lambert, Warner-Lambert Company will use its best efforts to expedite review and reduce the 45-day period.

1.7.1. Intellectual Property Rights

By signing a Clinical Study Agreement, the investigator agrees to keep in confidence and use only for completion of the study:

- Information provided to him/her by or on the behalf of Consumer Healthcare Research and Development; and
- Data, inventions, and discoveries, generated as a result of the study.

The investigator also agrees to return all copies of such information to Consumer Healthcare Research and Development at the sponsor’s request and that data, inventions, and discoveries generated during the course of this study shall be the property of Consumer Healthcare Research and Development and will sign any documents, if requested, to transfer such ownership. This obligation will not apply to any information or data that later becomes public knowledge.

1.8. Restriction for Subject Inclusion

Study site personnel and immediate family are excluded from enrollment.

2. DOCUMENTATION PROCEDURES

2.1. Information Required by Consumer Healthcare Research and Development for Regulatory Review
This study will not start in any country until the requirements of Consumer Healthcare Research and Development and all regulatory requirements for the country in which the trial will be conducted have been satisfied. The following documents and information must be provided by the principal investigator to Consumer Healthcare Research and Development:

2.1.1. Prior to Study Initiation

2.1.1.1. New Product Application (IND)

Signed protocol (and amendments, if applicable);

A completed, signed FDA Statement of Investigator (FDA Form 1572) for each principal investigator and co-principal investigator;

Current curriculum vitae for the principal investigator, co-principal investigators, and subinvestigators listed on 1572s;

Current and dated laboratory reference ranges for any laboratory listed on 1572s;

Current and dated laboratory certifications for any laboratory listed on 1572s;

IRB or EC approvals of the study protocol; amendments, when applicable; ICDs; and advertisements used to recruit subjects, if applicable. IRB/EC approvals should include specific reference to document approved, the formal name of the IRB/EC issuing the approval, and the signature of the chairperson of the IRB/EC or designate. If the IRB/EC reviewed a specific outline or abridgment of the protocol prepared by the investigator instead of the complete protocol, a copy of the document actually reviewed should also be supplied to Consumer Healthcare Research and Development.

Signed clinical study agreement and

Institutional review board/ethics committee membership list.

2.1.1.2. Non-IND Application

- Signed protocol (and amendments, if applicable);
- IRB/EC approvals of the study protocol; amendments, when applicable; ICDs; and advertisements used to recruit study subjects, if applicable
- Regulatory approval of protocol (and amendments), if dictated by local law;
- Current curriculum vitae for each principal investigator and co-principal investigator;
- Current laboratory reference ranges and certifications
- Signed clinical study agreement and
- Institutional review board/ethics committee membership list.
2.1.2. During the Study

Revisions or updates to any documents listed in Section 2.1.1;

Completed CRFs for each subject entered into the study;

All documents related to all serious adverse events and pregnancies and any reports to the IRB/EC describing serious adverse events or deaths either caused by or during use of the investigational drug; and

Investigator’s annual progress report to the IRB/EC, and a copy of the annual IRB/EC reapproval of the study upon which the report is based, if dictated by local law.

2.1.3. End-of-Study

Further revisions or updates to any documents listed in Section 2.1.1;

Completed subject CRFs not yet retrieved;

Investigator’s final report of the study, if applicable;

Investigator’s written notification to IRB/EC regarding study completion or discontinuation, if dictated by local law;

Signed Statement of Clinical Study Close-Out;

Signed Investigator Authorization of Data Clarification Letter.

Document Storage and Retention

Warner-Lambert policy requires that, following completion of a clinical study, the Principal Investigator must maintain all study records, including source documents, until otherwise notified by Warner-Lambert.

RECORDS MAY NOT BE DESTROYED OR DISCARDED WITHOUT THE WRITTEN PERMISSION OF WARNER-LAMBERT COMPANY.

Each completed original CRF, dated and signed by the investigator, and any data clarification forms (DCFs), dated and signed by the investigator, will be returned promptly to Warner-Lambert. A copy of each completed CRF and DRF must be retained at the site.

In order to assure the accuracy of data collected in the CRFs, it is mandatory that representatives of Warner-Lambert Company have access to original source documents. Source documents include subject records, subject charts, study records/worksheets, laboratory reports, etc. During the review of these documents, the anonymity of the subject will be respected, with strict adherence to professional standards of confidentiality. Warner-Lambert Company reserves the
right to terminate the study for refusal of the investigator to supply source documentation of work performance for this study.

2.2. **Guidelines for Recording Data in the Case Report Forms**

The completed CRF is a legal document as it may be intended for submission to a federal regulatory agency as part of a regulatory submission. Therefore, the following guidelines must be followed in its completion.

All data entered on the CRF must be in ink (not red). No data entry in the original CRF may be deleted or corrected by either erasure, use of ink eradication fluid, liquid paper, adhesive correction tape, or any other means. When a data entry is in error, draw a single line through the erroneous entry (the original data must remain discernible) and indicate the correct data in whatever way is appropriate. **All correction(s) with reason(s) for corrections (e.g., entry error) must be initialed and dated by one of the investigators or his/her designee.** Usually the initials should be near the corrected data, clearly associated with the specific correction being made;

Validity of data recorded on CRFs during each subject visit will be attested to by a dated signature. As indicated on each CRF, some must be signed by an investigator, others can be signed by a study coordinator;

All questions should be answered. If information cannot be provided, appropriately enter or mark a single line; NA for Not Applicable/Available; ND for Not Done; or UNK for Unknown;

Each page of the CRF must contain the subject’s initials, the subject’s ID number, as well as the study number in the spaces provided. In the interest of subject privacy, initials rather than full names should be used for identification. For the same reason, the social security number, address, or home telephone number of a subject should not be entered in the CRF.

The investigator is responsible for providing the completed original CRF for each subject to the Consumer Healthcare Research and Development Site Monitor/Clinical Research Associate. If the subject is hospitalized, the information in the CRF may be compared with the subject’s hospital records by the Consumer Healthcare Research and Development Site Monitor/Clinical Research Associate to verify its accuracy. If, because of institutional policy, only a copy of certain hospital records can be included in the CRF, the copy must be completely legible and either be signed or initialed in ink by the investigator. Since this verified copy will be considered as and dated the original by Consumer Healthcare Research and Development, the investigator is responsible for informing Consumer Healthcare Research and Development of any change that may be made in the “true” original that will be in the subject’s hospital records.

2.3. **Review of Case Report Forms**

The completed CRFs will be reviewed by Consumer Healthcare Research and Development Medical/Dental Colleagues, Site Monitor/Clinical Research Associates, and Clinical Data Management, or equivalent persons in a designated Contract Research Organization. The investigator will be contacted if any corrections or additions are necessary. The investigator is
Appendix E
Protocol #931-1309
May 9, 2000

responsible for cooperating fully with Consumer Healthcare Research and Development personnel or its designee in correcting any erroneous or contradictory data entries.

2.4. Investigator’s Responsibility for Clinical Product Supply Accountability

All clinical product supplies, i.e., new or marketed product, any corresponding placebo, and any active product control (including marketed formulations) in finished dosage form, provided by Consumer Healthcare Research and Development to the investigator for use in the clinical study must be accounted for in written documentation (i.e., records of receipt, dispensing, and return/destruction) that must be maintained and retained by the investigator and that will be monitored by Consumer Healthcare Research and Development personnel. Note: if applicable, the investigator may designate a pharmacist to be responsible for clinical product supply accountability.

2.4.1. Receipt of Clinical Product Supplies

The investigator must verify and acknowledge the receipt of clinical product supplies and retain related documentation (e.g., Investigational Drug Release Authorization form).

2.4.2. Storage

Product drug supplies must be maintained as specified in the protocol (e.g., environmental conditions required for stability) under secure (locked) conditions. Access to the stored study product should be limited to the investigators, the study coordinator, and the pharmacist (when applicable).

2.4.3. Dispensing of Clinical Product Supplies

Product dispensing records must be maintained. The investigator must assure completion of the product dispensing records with appropriate information (e.g., amount dispensed and returned by the subject, etc). The product dispensing records must be retained by the investigator along with the subject’s study records.

2.4.4. Return of Clinical Product Supplies

As specified in the protocol, all product containers and all unused product remaining at the termination or completion of the study must be returned to the address shown in the protocol or with the product shipment.

Used product containers should be maintained separately and returned periodically during the trial. The Consumer Healthcare Research and Development Site Monitor/Clinical Research Associate will assist in returning product and containers as required. The investigator must document on appropriate forms numbers of containers returned. All returned product provided by Consumer Healthcare Research and Development will be counted by Clinical and Consumer Packaging Operations as part of the study quality assurance audit and to meet regulatory requirements.
When applicable, any on-site product destruction must be pre-approved by Consumer Healthcare Research and Development, and actual product destruction must be documented.

3. PROTOCOL AMENDMENTS AND ADDENDA

Definitions

A protocol amendment is any systematic change (e.g., revision, addition, deletion) that is made to the Final Protocol for all sites from a clinical study and is identified by consecutive Arabic numerals (e.g., Amendment 1, Amendment 2, etc). Amendments can be made regardless of whether the protocol has been signed by the investigator or whether or not the protocol has been implemented at a site.

An Urgent Protocol Amendment is one that must be instituted quickly, usually to eliminate an apparent immediate hazard to subjects and may be implemented prior to eventual IRB/EC review (within 5 working days) and submission to regulatory authorities.

All amendments to the protocol must be approved by the principal investigator, the Consumer Healthcare Research and Development Medical/Dental colleague, the statistician, and the IRB/EC of the investigator’s institution. The investigator is responsible for submitting any proposed change in the approved protocol in writing to the IRB/EC for review and approval and for sending a copy of the approval to Consumer Healthcare Research and Development. All amendments will be filed with the FDA or appropriate regulatory authorities by the Regulatory Affairs Departments of Consumer Healthcare Research and Development.

With the exception indicated in Section 3.1 below, the amendment/addendum will apply to all subjects entered into the study (or all subjects in affected sites for addenda) after it has gone through the applicable procedure described above and been approved by the IRB/EC. Any amendments proposed in a multicenter protocol must be approved by the IRB/EC at the individual study site before it can be placed in effect at that site.

Protocol modifications or amendments fall into one of the following categories:

3.1. Urgent Protocol Amendment

If the amendment eliminates an apparent immediate safety hazard to the subject (urgent protocol amendment), it may be implemented immediately. Consumer Healthcare Research and Development will promptly notify the FDA and/or appropriate regulatory authorities of the amendment while the investigator will notify his/her IRB/EC of the change in writing within 5 working days of its implementation.

3.2. Other Amendments

Examples of protocol modifications requiring amendments to the Final Protocol and thus prior IRB/EC approval include:

Changes in the drug dosage or formulation;
Increases in subjects'/subjects' duration of exposure to drug;

Increases in subject numbers;

Significant changes in protocol design (e.g., drop/add control group)

Addition of a test/procedure that better monitors/reduces risk of side effects/adverse events;

Elimination of test intended to monitor safety;

Specific request from a regulatory agency;

Modification in entry (ie, inclusion/exclusion) or evaluability criteria;

Significant change in safety/efficacy status of the clinical test product;

Ambiguity (scientific or grammatical) in the protocol that needs clarification;

3.3. Study Termination

The Study may be terminated by Warner at any time in the exercise of its sole discretion upon fifteen (15) days prior written notice to Institution. The Study may be terminated by Institution upon fifteen (15) days prior written notice to Warner because of significant subject safety concerns or for other material and significant reasons. Upon receipt or giving of notice, as the case may be, Institution agrees to promptly terminate conduct of the Study to the extent medically permissible for all subjects. In the event of termination hereunder, other than as a result of a material breach by Institution, the total sums payable by Warner pursuant to this Agreement shall be equitably pro-rated for actual work performed to the date of termination with any unexpended funds previously paid by Warner to Institution being refunded to Warner.

3.4. Deviations from Protocol

A copy of the approved protocol will be kept on file at Warner-Lambert Company and the study site. Neither the investigator nor the sponsor are permitted to deviate from the protocol.

Apart from regulatory requirements, it is vital to the success of the study that the investigator adheres to the details of the protocol and thus, holds to a minimum the number of cases later classified as 'incomplete' or 'unusable.'

When a situation occurs that requires departure from the protocol, the investigator will contact the study monitor. Contact with the study monitor will be made as soon as possible in order to discuss the situation and to agree on an appropriate course of action.

Warner-Lambert Company reserves the right not to compensate the investigator for evaluation of cases in which the procedures and evaluations are conducted in a manner other than that specified by the protocol.
APPENDIX F

The Declaration of Helsinki

The Declaration of Helsinki

Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects

Adopted by the 18th World Medical Assembly
Helsinki, Finland, June 1964,

and amended by
the 29th World Medical Assembly, Tokyo, Japan, October 1975;
the 35th World Medical Assembly, Venice, Italy, October 1983;
the 41st World Medical Assembly, Hong Kong, September 1989;

and the
48th General Assembly, Somerset West, Republic of South Africa, October 1996
TABLE OF CONTENTS

INTRODUCTION ............................................................................... F-3

I. BASIC PRINCIPLES..................................................................... F-3

II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE (CLINICAL RESEARCH) ............................................................................................................................................................................................................. F-5

III. NONTHERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (NON-CLINICAL BIOMEDICAL RESEARCH) .............. F-5
INTRODUCTION

It is the mission of the physician to safeguard the health of the people. His or her knowledge and conscience are dedicated to the fulfillment of this mission.

The Declaration of Geneva of the World Medical Association binds the physician with the words, "The health of my subject will be my first consideration," and the International Code of Medical Ethics declares that, "A physician shall act only in the subject's interest when providing medical care which might have the effect of weakening the physical and mental condition of the subjects."

The purpose of biomedical research involving human subjects must be to improve diagnostic, therapeutic, and prophylactic procedures and the understanding of the etiology and pathogenesis of disease.

In current medical practice most diagnostic, therapeutic, or prophylactic procedures involve hazards. This applies especially to biomedical research.

Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects.

In the field of biomedical research a fundamental distinction must be recognized between medical research in which the aim is essentially diagnostic or therapeutic for a subject, and medical research, the essential object of which is purely scientific and without implying direct diagnostic or therapeutic value to the person subjected to the research.

Special caution must be exercised in the conduct of research which may affect the environment, and the welfare of animals used for research must be respected.

Because it is essential that the results of laboratory experiments be applied to human beings to further scientific knowledge and to help suffering humanity, the World Medical Association has prepared the following recommendations as a guide to every physician in biomedical research involving human subjects. They should be kept under review in the future. It must be stressed that the standards as drafted are only a guide to physicians all over the world. Physicians are not relieved from criminal, civil, and ethical responsibilities under the laws of their own countries.

I. Basic Principles

A. Biomedical research involving human subjects must conform to generally accepted scientific principles and should be based on adequately performed laboratory and animal experimentation and on a thorough knowledge of the scientific literature.
B. The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol which should be transmitted for consideration, comment, and guidance to a specially appointed committee independent of the investigator and the sponsor provided that this independent committee is in conformity with the laws and regulations of the country in which the research experiment is performed.

C. Biomedical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given his or her consent.

D. Biomedical research involving human subjects cannot legitimately be carried out unless the importance of the objective is in proportion to the inherent risk to the subject.

E. Every biomedical research project involving human subjects should be preceded by careful assessment of predictable risks in comparison with foreseeable benefits to the subject or to others. Concern for the interests of the subject must always prevail over the interests of science and society.

F. The right of the research subject to safeguard his or her integrity must always be respected. Every precaution should be taken to respect the privacy of the subject and to minimize the impact of the study on the subject’s physical and mental integrity and on the personality of the subject.

G. Physicians should abstain from engaging in research projects involving human subjects unless they are satisfied that the hazards involved are believed to be predictable. Physicians should cease any investigation if the hazards are found to outweigh the potential benefits.

H. In publication of the results of his or her research, the physician is obliged to preserve the accuracy of the results. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.

I. In any research on human beings, each potential subject must be adequately informed of the aims, methods, anticipated benefits, and potential hazards of the study and the discomfort it may entail. He or she should be informed that he or she is at liberty to abstain from participation in the study and that he or she is free to withdraw his or her consent to participation at any time. The physician should then obtain the subject’s freely given informed consent, preferably in writing.

J. When obtaining informed consent for the research project, the physician should be particularly cautious if the subject is in a dependent relationship to him or her or may consent under duress. In that case the informed consent should be obtained by a physician who is not engaged in the investigation and who is completely independent of this official relationship.
K. In case of legal incompetence, informed consent should be obtained from the legal guardian in accordance with national legislation. Where physical or mental incapacity makes it impossible to obtain informed consent, or when the subject is a minor, permission from the responsible relative replaces that of the subject in accordance with national legislation.

Whenever the minor child is in fact able to give a consent, the minor’s consent must be obtained in addition to the consent of the minor’s legal guardian.

L. The research protocol should always contain a statement of the ethical considerations involved and should indicate that the principles enunciated in the present Declaration are complied with.

II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE (CLINICAL RESEARCH)

A. In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic measure, if in his or her judgment it offers hope of saving life, reestablishing health, or alleviating suffering.

B. The potential benefits, hazards, and discomfort of a new method should be weighed against the advantages of the best current diagnostic and therapeutic methods.

C. In any medical study, every subject - including those of a control group, if any - should be assured of the best proven diagnostic and therapeutic methods. This does not exclude the use of inert placebo in studies where no proven diagnostic or therapeutic method exists.

D. The refusal of the subject to participate in a study must never interfere with the physician-subject relationship.

E. If the physician considers it essential not to obtain informed consent, the specific reasons for this proposal should be stated in the experimental protocol for transmission to the independent committee.(I,B)

F. The physician can combine medical research with professional care, the objective being the acquisition of new medical knowledge, only to the extent that medical research is justified by its potential diagnostic or therapeutic value for the subject.

III. NONTHERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (NON-CLINICAL BIOMEDICAL RESEARCH)

A. In the purely scientific application of medical research carried out on a human being, it is the duty of the physician to remain the protector of the life and health of that person on whom biomedical research is being carried out.
B. The subjects should be volunteers - either healthy persons or subjects for whom the experimental design is not related to the subject’s illness.

C. The investigator or the investigating team should discontinue the research if in his/her or their judgment it may, if continued, be harmful to the individual.

D. In research on man, the interest of science and society should never take precedence over considerations related to the well-being of the subject.
Appendix G

Case Report Forms:

<table>
<thead>
<tr>
<th>Form</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening Form and Medical History</td>
<td>G-2</td>
</tr>
<tr>
<td>Oral Tissue Exam</td>
<td>G-3</td>
</tr>
<tr>
<td>Modified Gingival Index</td>
<td>G-4</td>
</tr>
<tr>
<td>Bleeding Index</td>
<td>G-5</td>
</tr>
<tr>
<td>Plaque Index</td>
<td>G-6</td>
</tr>
<tr>
<td>Adverse Event Form</td>
<td>G-7</td>
</tr>
<tr>
<td>Serious Adverse Event Form</td>
<td>G-8</td>
</tr>
<tr>
<td>Concomitant Medication Form</td>
<td>G-9</td>
</tr>
<tr>
<td>Subject Discontinuation Form</td>
<td>G-10</td>
</tr>
</tbody>
</table>
SUBJECT ELIGIBILITY/SCREENING FORM
STUDY #931-1309

USE BLACK BALL-POINT PEN

Subject’s Initials ____________________ Subject’s # _____________ Date ________________

Age _____ Gender ____ (M/F) _____ Race __________ (AI,A,AA,II,W,PI) _____ Smoking _____ (Y/N)

INCLUSION/EXCLUSION CRITERIA

1. Age range: 18 - 65 years old. YES NO
2. A minimum of 20 natural teeth with 2 scorable surfaces (facial and lingual). YES NO
3. Has read, signed, and received a copy of the Informed Consent Form after the nature of the study has been fully explained. YES NO

FOR INCLUSION, RESPONSES TO QUESTIONS 1-3 MUST BE “YES”

4. History of significant adverse effects following use of oral hygiene products such as toothpastes and mouthrinses (colorings may cause allergic reactions including asthma this is more common in people allergic to aspirin). YES NO
5. History of rheumatic fever or other conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures. YES NO
6. History of diabetes, hepatic or renal disease, or other serious medical conditions or transmittable diseases. YES NO
7. Self reported pregnancy or lactation. YES NO
8. Participation, concurrently or within last 30 days, in a dental plaque/gingivitis study involving oral care products. YES NO
9. Use of antibiotic, antiinflammatory or anticoagulant therapy during past month, if yes then complete a concomitant medication form. YES NO
10. Fixed or removable partial dentures, orthodontic bands, or appliances. YES NO
11. Gross dental caries, severe generalized cervical and/or enamel abrasion, large, fractured or temporary restorations. YES NO
12. Significant oral soft tissue pathology, excluding gingivitis, based on visual examination. YES NO
13. Moderate/advanced periodontitis (ADA Class III, IV). YES NO
14. History of alcoholism. YES NO

FOR INCLUSION, RESPONSES TO QUESTIONS 4-13 MUST BE “NO”

IS SUBJECT ELIGIBLE TO BE ENROLLED INTO THE STUDY? YES NO

Interviewer’s Signature ________________________________ Date __________________
Examiner’s Signature ________________________________ Date __________________
CLINICAL EXAMINATION FORM

Study #931-1309

ORAL EXAMINATION

USE BLACK BALLPOINT PEN

Subject's Initials ___________________________ Subject's No. _______________

CIRCLE EXAMINATION PERIOD:

<table>
<thead>
<tr>
<th>Baseline</th>
<th>Final</th>
<th>Date of Examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condition of:</td>
<td>Normal</td>
<td>Describe abnormality</td>
</tr>
<tr>
<td>lips</td>
<td></td>
<td></td>
</tr>
<tr>
<td>buccal mucosa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>labial mucosa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sublingual mucosa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>attached gingivae</td>
<td></td>
<td></td>
</tr>
<tr>
<td>tongue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hard/soft palate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>uvula</td>
<td></td>
<td></td>
</tr>
<tr>
<td>oropharynx</td>
<td></td>
<td></td>
</tr>
<tr>
<td>teeth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>other</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abnormality attributable to experimental oral rinse? Yes ____ No ____ NA

Comments:

Date
Signed _______________ Examiner __________________
CLINICAL EXAMINATION FORM  
STUDY #931-1309

USE BLACK BALLPOINT PEN

Subject Initials _______ Subject No. _______ Date of Examination ____________

(Circle One) Baseline Final

MODIFIED GINGIVAL INDEX

<table>
<thead>
<tr>
<th>MAX</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>P</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>P</td>
<td>M</td>
</tr>
<tr>
<td>P</td>
<td>M</td>
<td>P</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>P</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>P</td>
<td>M</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MAN</th>
<th>31</th>
<th>30</th>
<th>29</th>
<th>28</th>
<th>27</th>
<th>26</th>
<th>25</th>
<th>24</th>
<th>23</th>
<th>22</th>
<th>21</th>
<th>20</th>
<th>19</th>
<th>18</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>P</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>P</td>
<td>M</td>
</tr>
<tr>
<td>P</td>
<td>M</td>
<td>P</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>P</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>P</td>
<td>M</td>
</tr>
</tbody>
</table>

Examiner's Signature ___________________________ Date _____________
CLINICAL EXAMINATION FORM
STUDY #931-1309

USE BLACK BALLPOINT PEN

Subject's Initials  Subject's #  Date  Baseline  Final (Circle One)

BLEEDING INDEX

<table>
<thead>
<tr>
<th></th>
<th>SUR</th>
<th>UPPER RIGHT</th>
<th>SUR</th>
<th>UPPER LEFT</th>
<th>SUR</th>
<th>LINGUAL</th>
<th>SUR</th>
<th>LINGUAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Examiner's Signature  Date
USE BLACK BALLPOINT PEN

Subject Initials

Subject No. ___

Date of Examination ___

CIRCLE ONE:

Baseline    Final

Q-H PLAQUE INDEX

<table>
<thead>
<tr>
<th>Max</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fac</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mand</td>
<td>31</td>
<td>30</td>
<td>29</td>
<td>28</td>
<td>27</td>
<td>26</td>
<td>25</td>
<td>24</td>
<td>23</td>
<td>22</td>
<td>21</td>
<td>20</td>
<td>19</td>
<td>18</td>
</tr>
<tr>
<td>Fac</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comments:

Examiner's Signature ___________________________  Date Signed ___________________________
**STUDY ADVERSE EVENTS**

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Site Number</th>
<th>Subject Initials</th>
<th>Subject Number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(First, Middle, Last)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADVERSE EVENTS DIAGNOSIS ONLY (IF KNOWN) OR SIGNS/SYMPTOMS (LIST ONE PER LINE)</th>
<th>DATE OF ONSET</th>
<th>FREQUENCY</th>
<th>SEVERITY</th>
<th>OUTCOME</th>
<th>DATE OF RESOLUTION OR DEATH</th>
<th>DURATION OF EVENT IF LESS THAN 24 HOURS (HOURS : MIN)</th>
<th>RELATIONSHIP WITH STUDY MEDICATION</th>
<th>ACTION TAKEN</th>
<th>Does the event meet the definition of SERIOUS?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y=Yes or N=No (see definitions)*</td>
</tr>
</tbody>
</table>

*DEFINITIONS:*
- **Serious** means the experience was fatal or life-threatening (see definition below), required or prolonged in-patient hospitalization, was significantly disabling or incapacitating, is a congenital anomaly, or is considered otherwise medically significant.
- **Life-threatening** means the subject was, in the view of the Investigator, at immediate risk of death from the event as it occurred. It does not include an event that, had it occurred in a more serious form, might have caused death.

**DEFINITIONS:**

Serious means the experience was fatal or life-threatening (see definition below), required or prolonged in-patient hospitalization, was significantly disabling or incapacitating, is a congenital anomaly, or is considered otherwise medically significant.

Life-threatening means the subject was, in the view of the Investigator, at immediate risk of death from the event as it occurred. It does not include an event that, had it occurred in a more serious form, might have caused death.

**ACTION TAKEN**

- **WITH STUDY DRUG**
  - Y=Yes
  - N=No
- **DOSAGE**
  - Adjusted
- **PRESERVED MEDICATION**
  - To treat the event?
  - Y=Yes
  - N=No
- **EVENT?**
  - If yes, record on concurrent medication page

**INVESTIGATOR**

Signature

Date
**RECENT MEDICATION HISTORY**

Please list any medications, both prescription and non-prescription, subject has taken in the last month or has taken periodically (e.g., Tylenol for headache or PMS).

<table>
<thead>
<tr>
<th>Drug (List one per line)</th>
<th>Unit Dose</th>
<th>Units</th>
<th>Freq.</th>
<th>Route</th>
<th>DATE STARTED</th>
<th>DATE STOPPED</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DATE</td>
<td>DATE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Month Day Year</td>
<td>Month Day Year</td>
<td></td>
</tr>
</tbody>
</table>

**Comments:**

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

Investigator Signature: ____________________________ Date: ______________________
SUBJECT DISCONTINUATION FORM

STUDY # ____________________

USE BLACK BALL-POINT PEN

SUBJECT'S INITIALS _______ SUBJECT'S # ______ DATE _____________

DATE OF DISCONTINUATION OF STUDY TEST PRODUCT:   [ ] Month [ ] Day [ ] Year

INDICATE REASON(S) FOR SUBJECT WITHDRAWAL/DISCONTINUATION &
DESCRIBE

<table>
<thead>
<tr>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse Event (Briefly Describe):</td>
</tr>
<tr>
<td>Protocol Violation/Non compliance/Subject falls into study exclusion criteria:</td>
</tr>
<tr>
<td>Administrative Reason (e.g., subject moved, work schedule conflicts, etc.):</td>
</tr>
<tr>
<td>Subject Personal Reasons (e.g., decided not to participate, procedures too demanding, etc.):</td>
</tr>
<tr>
<td>Reason unknown (subject did not return, lost to follow-up, etc.):</td>
</tr>
<tr>
<td>Other (Explain):</td>
</tr>
</tbody>
</table>

Product Code Broken? YES NO (Circle one)

If yes, please explain: __________________________________________________________
______________________________________________________________________________
______________________________________________________________________________

Investigator's Signature __________________________ Date Signed ________________